These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 28356064)

  • 1. Protocol of the PANCALYZE trial: a multicenter, prospective study investigating the tumor biomarkers CXCR4, SMAD4, SOX9 and IFIT3 in patients with resected pancreatic adenocarcinoma to predict the pattern of recurrence of the disease.
    Popp FC; Popp MC; Zhao Y; Betzler C; Kropf S; Garlipp B; Benckert C; Kalinski T; Lippert H; Bruns CJ
    BMC Cancer; 2017 Mar; 17(1):229. PubMed ID: 28356064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of CXCR4 and SMAD4 in predicting disease progression pattern and benefit from adjuvant chemotherapy in resected pancreatic adenocarcinoma.
    Bachet JB; Maréchal R; Demetter P; Bonnetain F; Couvelard A; Svrcek M; Bardier-Dupas A; Hammel P; Sauvanet A; Louvet C; Paye F; Rougier P; Penna C; Vaillant JC; André T; Closset J; Salmon I; Emile JF; Van Laethem JL
    Ann Oncol; 2012 Sep; 23(9):2327-2335. PubMed ID: 22377565
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study.
    Shin SH; Kim HJ; Hwang DW; Lee JH; Song KB; Jun E; Shim IK; Hong SM; Kim HJ; Park KM; Lee YJ; Kim SC
    Oncotarget; 2017 Mar; 8(11):17945-17959. PubMed ID: 28160547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-Induced Protein With Multiple Tetratricopeptide Repeats 3 Is Associated With Response to Chemotherapy and Recurrence but Not With Survival.
    Popp MC; Klippstein M; Lohneis P; Kalinski T; Li J; Quaas A; Bludau M; Wang Z; Waldschmidt D; Kunzmann V; Damanakis A; Gebauer F; Zhao Y; Bruns CJ; Popp FC
    Pancreas; 2020; 49(10):1307-1314. PubMed ID: 33122518
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma.
    Xia S; Feng Z; Qi X; Yin Y; Jin J; Wu Y; Wu H; Feng Y; Tao M
    Med Oncol; 2015 Jan; 32(1):358. PubMed ID: 25428381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
    Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
    PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphatase PPM1A is a novel prognostic marker in pancreatic ductal adenocarcinoma.
    Fan J; Yang MX; Ouyang Q; Fu D; Xu Z; Liu X; Mino-Kenudson M; Geng J; Tang F
    Hum Pathol; 2016 Sep; 55():151-8. PubMed ID: 27195906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intratumoral Heterogeneity of SMAD4 Immunohistochemical Expression and Its Role in Prediction of Recurrence Pattern in Patients with Resectable Pancreatic Cancer.
    Pokataev I; Kudaibergenova A; Artemyeva A; Popova A; Rumyantsev A; Podluzhny D; Kudashkin N; Fedyanin M; Tryakin A; Tjulandin S
    J Gastrointest Cancer; 2019 Sep; 50(3):478-484. PubMed ID: 29675723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure patterns in resected pancreas adenocarcinoma: lack of predicted benefit to SMAD4 expression.
    Winter JM; Tang LH; Klimstra DS; Liu W; Linkov I; Brennan MF; DʼAngelica MI; DeMatteo RP; Fong Y; Jarnagin WR; Oʼreilly EM; Allen PJ
    Ann Surg; 2013 Aug; 258(2):331-5. PubMed ID: 23360922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Smad4 loss in esophageal adenocarcinoma is associated with an increased propensity for disease recurrence and poor survival.
    Singhi AD; Foxwell TJ; Nason K; Cressman KL; McGrath KM; Sun W; Bahary N; Zeh HJ; Levy RM; Luketich JD; Davison JM
    Am J Surg Pathol; 2015 Apr; 39(4):487-95. PubMed ID: 25634752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of krüppel-like factor 10 or Smad4 predicts clinical benefit of adjuvant chemoradiotherapy in curatively resected pancreatic adenocarcinoma: From a randomized phase III trial.
    Pen SL; Shan YS; Hsiao CF; Liu TW; Chen JS; Ho CL; Chou WC; Hsieh RK; Chen LT; Ch'ang HJ
    Radiother Oncol; 2021 May; 158():146-154. PubMed ID: 33667587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DPC4/Smad4 expression and outcome in pancreatic ductal adenocarcinoma.
    Biankin AV; Morey AL; Lee CS; Kench JG; Biankin SA; Hook HC; Head DR; Hugh TB; Sutherland RL; Henshall SM
    J Clin Oncol; 2002 Dec; 20(23):4531-42. PubMed ID: 12454109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor and DPC4 predict adjuvant therapy outcomes in resected pancreatic cancer.
    Khorana AA; Hu YC; Ryan CK; Komorowski RA; Hostetter G; Ahrendt SA
    J Gastrointest Surg; 2005; 9(7):903-11. PubMed ID: 16137582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgery and multimodal treatments in pancreatic cancer--a review on the basis of future multimodal treatment concepts.
    Link KH; Leder G; Formentini A; Fortnagel G; Kornmann M; Schatz M; Beger HG
    Gan To Kagaku Ryoho; 1999 Jan; 26(1):10-40. PubMed ID: 9987495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SMAD4 expression predicts local spread and treatment failure in resected pancreatic cancer.
    Yamada S; Fujii T; Shimoyama Y; Kanda M; Nakayama G; Sugimoto H; Koike M; Nomoto S; Fujiwara M; Nakao A; Kodera Y
    Pancreas; 2015 May; 44(4):660-4. PubMed ID: 25760429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemically detected expression of 3 major genes (CDKN2A/p16, TP53, and SMAD4/DPC4) strongly predicts survival in patients with resectable pancreatic cancer.
    Oshima M; Okano K; Muraki S; Haba R; Maeba T; Suzuki Y; Yachida S
    Ann Surg; 2013 Aug; 258(2):336-46. PubMed ID: 23470568
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized Management of Pancreatic Ductal Adenocarcinoma Patients through Computational Modeling.
    Yamamoto KN; Yachida S; Nakamura A; Niida A; Oshima M; De S; Rosati LM; Herman JM; Iacobuzio-Donahue CA; Haeno H
    Cancer Res; 2017 Jun; 77(12):3325-3335. PubMed ID: 28381541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SOX9 expression predicts relapse of stage II colon cancer patients.
    Marcker Espersen ML; Linnemann D; Christensen IJ; Alamili M; Troelsen JT; Høgdall E
    Hum Pathol; 2016 Jun; 52():38-46. PubMed ID: 26980019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.